SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Akums Drugs and Pharmaceuticals informs about press release

14 May 2026 Evaluate

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Akums Drugs and Pharmaceuticals has informed that it enclosed a copy of press release titled, ‘Akums reports Q4 FY26 and full year FY26 results with healthy top line and strong EBITDA growth; Board recommends dividend’.

The above information is a part of company’s filings submitted to BSE.

Akums Drugs & Pharma Share Price

650.60 26.30 (4.21%)
07-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1903.00
Dr. Reddys Labs. 1353.75
Cipla 1452.35
Zydus Lifesciences 1152.90
Lupin 2489.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: